Jenni Björnulfson appointed as new CFO of Peptonic Medical
Peptonic Medical AB (publ) ("Peptonic") announces the appointment of Jenni Björnulfson as the company's new Chief Financial Officer (CFO). Jenni will assume the position on September 1, 2024, replacing Albert Lindgren. During the transition period until Jenni assumes office, Daniel Rudeklint will serve as Acting CFO.
Expressing enthusiasm for the appointment, Peptonic’s CEO looks forward to welcoming Jenni to the company. "Jenni brings with her a solid experience in finance and possesses a profound understanding of both public companies and the life science industry. I am confident that her experience and expertise will significantly contribute to Peptonic's continued development," says Anna Linton.
Jenni joins Peptonic from Lidds AB, where she has served as CFO since 2021 and assumed the role of CEO in December 2023. Previous roles include CFO for Promore Pharma and Cinclus Pharma, alongside positions as a stock analyst at ABG Sundal Collier and in corporate finance at Alfred Berg and Handelsbanken. Jenni holds a master's degree from the Stockholm School of Economics and has undertaken studies at the Karolinska Institute.
During the transition period, Daniel Rudeklint will undertake the role of Acting CFO. Daniel, currently a board member of Peptonic, possesses a deep understanding of the company's operations. With experience as both CEO and CFO, as well as holding board positions in both listed and unlisted companies, Daniel brings invaluable expertise to his interim role.
For further information, please contact:
Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic
Peptonic Medical AB (publ) is a cutting-edge Swedish biomedical company, dedicated in the development and distribution of clinically proven self-care treatments and self-diagnostic tests in intimate women's health. The portfolio is sold under the brands Vagivital and Vernivia. The company's vision is to revolutionize intimate health by empowering women to diagnose, treat, and prevent intimate medical conditions independently and effectively.
Central to the growth strategy is the geographical expansion of VagiVital and Verniva through local partners. Peptonic Medical also intends to continuously broaden the company's product portfolio through acquisitions and the development of innovative and competitive products in-house. The company's mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio.
The company is headquartered in Stockholm, Sweden, and has subsidiaries Common Sense Marketing Inc in the USA and Peptonic Medical Ltd in Israel. Peptonic Medical was founded in 2009, and the company's shares have been listed on the Spotlight Stock Market since 2014